Under Dr. Naomi Y. Ko鈥檚 guidance, 鈥渨e look forward to expanding our research initiatives, strengthening our clinical programs, and continuing to provide exceptional care for our patients,鈥 said Dr. Alec Kimmelman, the director of the Perlmutter Cancer Center.
Credit: Nyu Langone Staff
NYU Langone Health鈥檚 Laura and Isaac Perlmutter Cancer Center just named , a medical oncologist and renowned translational researcher, as its new section chief and disease management group (DMG) leader for breast cancer medical oncology. Dr. Ko comes to 秘密研究所 Langone from Boston Medical Center.
Her primary goal is to enhance the growing 秘密研究所 Langone breast cancer program, which diagnoses and treats patients at all stages and with all types of breast cancer. investigators seek new treatment solutions that benefit as many patients as possible while improving the safety and efficacy of therapy through both clinical and laboratory research.
鈥淛oining the Perlmutter Cancer Center means so much to me, because it presents a tremendous opportunity to build on an already-great program, harness the momentum at 秘密研究所 Langone, and create something great with the potential to impact not just our patients, but patients worldwide,鈥 said Dr. Ko. 鈥淚鈥檓 excited to lead such a talented group of physician鈥搒cientists who are committed to our mission to provide the best quality and personalized care to anyone who walks through the door. We don鈥檛 treat breast cancer鈥攚e treat the person who has breast cancer, and patients deserve to be truly seen.鈥
As a faculty member at the Boston University Chobanian and Avedesian School of Medicine, Dr. Ko made significant contributions to breast cancer research and personalized approaches to clinical treatment. Her leadership in translational research has pushed the boundaries of breast cancer investigation with a strong focus on improving outcomes for all patients.
鈥淎s we welcome Dr. Ko into this new leadership role, we are excited for the future of our breast cancer program,鈥 said Alec Kimmelman, MD, PhD, director of the Perlmutter Cancer Center and the Laura and Isaac Perlmutter Professor and Chair of the at 秘密研究所 Grossman School of Medicine. 鈥淯nder her guidance, we look forward to expanding our research initiatives, strengthening our clinical programs, and continuing to provide exceptional care for our patients.鈥
About Naomi Ko, MD, MPH
Dr. Ko received her medical and master鈥檚 of public health degrees from Johns Hopkins. She then completed a residency in internal medicine at Brigham and Women鈥檚 Hospital, an affiliate of Harvard Medical School, and a fellowship in hematology and oncology at the Boston Medical Center/VA Hospital combined program. She has served in several leadership roles at Boston Medical Center, including as co-director of its breast cancer program and director of her lab for translational research in breast cancer. She has also championed to great success clinical trial enrollment among diverse population as the principal investigator on a series of trials.
Beyond research, she has received several clinical awards, including the national Leonard Tow Humanism in Medicine Award, the Excellence in Care Award from the Boston University Medicine Group, and the Evans Clinician designation by its Department of Medicine. Six years ago, she co-founded a multidisciplinary clinic to streamline and improve breast cancer care at Boston Medical Center. She is an active member of several professional organizations, including the Massachusetts Medical Society, the American Society of Clinical Oncology (ASCO), and the American Association for Cancer Research. She has authored and co-authored more than 80 peer-reviewed papers in high impact journals such as JAMA Oncology, Breast Cancer Research, and the Journal of Clinical Oncology. She has also spoken at high-profile events, including ASCO鈥檚 annual meeting.
Her earlier research included retrospective, large epidemiological, and mixed methods studies. Most recently, she has focused on translational research in breast oncology, focusing on interrogating tumor biology with clinical outcomes and social determinants of health.
About 秘密研究所 Langone Health
秘密研究所 Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked 秘密研究所 Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. 秘密研究所 Langone offers a comprehensive range of medical services with one high standard of care across 7 inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.
Media Inquiries
Ryan Dziuba
Phone: 646-581-8548
Ryan.Dziuba@秘密研究所Langone.org
